SCHEMBL5369490

SCHEMBL5369490

CNS(=O)(=O)c1ccc2c(c1)C(=Cc1cc(Cl)c(OCc3ccccc3)c(C(C)(C)C)c1)C(=O)N2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 5/20 0.47
EGFR P00533 3/20 0.45
IGF1R P08069 1/20 0.43
SRC P12931 4/20 0.43
CDK2 P24941 2/20 0.42
KDR P35968 2/20 0.42
RAF1 P04049 1/20 0.42
NTRK1 P04629 1/20 0.41
FCER2 P06734 1/20 0.41
SYK P43405 1/20 0.41
NTRK3 Q16288 1/20 0.41
NTRK2 Q16620 1/20 0.41
PPARG P37231 1/20 0.41
LRRK2 Q5S007 1/20 0.40
AURKA O14965 1/20 0.40
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40
APH1A Q96BI3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5361957 0.94 ERBB2 (0.48) ERBB2EGFRIGF1RSRCCDK2
SCHEMBL5364381 0.90 ERBB2 (0.45) ERBB2EGFRIGF1RSRCCDK2
SCHEMBL5362797 0.90 ERBB2 (0.56) ERBB2EGFRIGF1RSRCCDK2
SCHEMBL5377229 0.88 AR (0.47) ERBB2EGFRIGF1RRAF1LRRK2
SCHEMBL5373158 0.87 ERBB2 (0.59) ERBB2EGFRIGF1RSRCCDK2
SCHEMBL5363020 0.86 ERBB2 (0.54) ERBB2EGFRIGF1RSRCCDK2
SCHEMBL5358336 0.85 ERBB2 (0.52) ERBB2EGFRIGF1RRAF1NTRK1
SCHEMBL5368362 0.84 SRC (0.49) SRCCDK2KDRNTRK1FCER2
SCHEMBL5376624 0.83 ERBB2 (0.50) ERBB2EGFRIGF1RRAF1PPARG
SCHEMBL5403860 0.83 AR (0.50) ERBB2EGFRIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK ERBB2 19/4885EGFR 286/4885IGF1R 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.